Form 4: Rhythm Pharmaceuticals Executive Exercises Options and Sells Shares Under Pre-Arranged Plan

Rhythm Pharmaceuticals' Corporate Controller & CAO, Christopher Paul German, executed a series of transactions on July 9, 2025, involving the exercise of stock options and subsequent sale of common stock under a Rule 10b5-1 trading plan.

Summary

• Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, Inc. (RYTM), engaged in multiple transactions on July 9, 2025.
• Exercised stock options to acquire 2,000 shares of common stock at an exercise price of $17.97 per share.
• Exercised additional stock options to acquire 850 shares of common stock at an exercise price of $49.23 per share.
• Sold 1,967 shares of common stock at a price of $76.75 per share.
• Sold an additional 1,850 shares of common stock at a price of $85.00 per share.
• All reported sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. German on March 11, 2025.
• Following these transactions, Mr. German's direct beneficial ownership of Rhythm Pharmaceuticals common stock decreased to 922 shares.
• Remaining unexercised derivative securities include 6,231 stock options with an exercise price of $17.97 and an expiration date of April 3, 2033.
• Also remaining are 4,550 stock options with an exercise price of $49.23 and an expiration date of February 15, 2034.

Sentiment

Score: 5

Explanation: The document reports routine insider transactions involving option exercises and subsequent sales under a pre-arranged trading plan, which is a common practice for executive compensation and liquidity. While there is a net reduction in direct share ownership, the 10b5-1 plan mitigates negative sentiment as the sales were pre-scheduled.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions rather than a reaction to new, non-public information.
• The exercise of stock options demonstrates the executive's realization of value from previously granted equity compensation.

Negatives

• There was a net reduction of 967 shares in the direct common stock holdings of a key executive (from an inferred 1,889 shares to 922 shares).
• The sales occurred at prices significantly higher than the exercise prices, indicating profit-taking by the executive.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception of insider selling, which is mitigated by the 10b5-1 plan.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: May observe a net reduction in direct share ownership by a key executive, though the pre-arranged nature of the sales (10b5-1 plan) typically lessens concerns about reactive selling based on new, negative information.

Key Dates

Recommendation

Keywords

Rhythm Pharmaceuticals, RYTM, Form 4, insider trading, stock options, share sale, executive compensation, Christopher Paul German, 10b5-1 plan